Global CDMO Scale End-to-end cell and gene therapy manufacturing from development to commercialization, with globally distributed facilities in the UK, France, and the US, enabling clients to scale programs faster and meet regulatory standards.

Tech Platform Advantage Proprietary platforms such as the TetraVecta fourth generation lentiviral system and dual plasmid AAV production offer higher yields, robust quality, and smoother technology transfer for mid to late stage and commercial programs.

US Footprint Growth Strategic expansion in North Carolina and ongoing US capacity build provide near shore capabilities for North American sponsors, reducing supply chain risk and accelerating timelines.

Industry Leadership Consistent recognition as an innovative, global CDMO in cell and gene therapy boosts credibility with prospective clients and supports competitive positioning for multi-year collaborations.

Partnership Momentum Active licensing and partnerships, including a collaboration with Viral Vector Manufacturing Facility, signals strong business development momentum and creates cross-sell opportunities across development, fill finish, and commercial manufacturing.